{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:42:01Z","timestamp":1788954121789,"version":"build-2803163510"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-16-1-0196"],"award-info":[{"award-number":["W81XWH-16-1-0196"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016359"],"award-info":[{"award-number":["P30CA016359"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s43032-024-01585-w","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T17:01:52Z","timestamp":1715619712000},"page":"2150-2162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["ARID1A in Gynecologic Precancers and Cancers"],"prefix":"10.1007","volume":"31","author":[{"given":"Jaida E.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishah","family":"Jaferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Shonibare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-888X","authenticated-orcid":false,"given":"Gloria S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"issue":"2","key":"1585_CR1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrc1273","volume":"4","author":"CW Roberts","year":"2004","unstructured":"Roberts CW, Orkin SH. The SWI\/SNF complex\u2013chromatin and cancer. Nat Rev Cancer. 2004;4(2):133\u201342.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1585_CR2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4161\/cbt.28411","volume":"15","author":"RC Wu","year":"2014","unstructured":"Wu RC, Wang TL, Shih IM. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther. 2014;15(6):655\u201364.","journal-title":"Cancer Biol Ther"},{"key":"1585_CR3","doi-asserted-by":"crossref","first-page":"102287","DOI":"10.1016\/j.ctrv.2021.102287","volume":"100","author":"J Mullen","year":"2021","unstructured":"Mullen J, et al. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100:102287.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"1585_CR4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/path.5849","volume":"256","author":"K Heinze","year":"2022","unstructured":"Heinze K, et al. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8(+) TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol. 2022;256(4):388\u2013401.","journal-title":"J Pathol"},{"issue":"5","key":"1585_CR5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"key":"1585_CR6","doi-asserted-by":"crossref","unstructured":"Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.","DOI":"10.1126\/scisignal.2004088"},{"issue":"23","key":"1585_CR7","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn I, et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83(23):3861\u20137.","journal-title":"Cancer Res"},{"issue":"6001","key":"1585_CR8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","volume":"330","author":"S Jones","year":"2010","unstructured":"Jones S, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228\u201331.","journal-title":"Science"},{"issue":"11","key":"1585_CR9","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1101\/gr.137596.112","volume":"22","author":"H Liang","year":"2012","unstructured":"Liang H, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012;22(11):2120\u20139.","journal-title":"Genome Res"},{"issue":"4","key":"1585_CR10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ijc.32140","volume":"145","author":"YB Kim","year":"2019","unstructured":"Kim YB, et al. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019;145(4):916\u201326.","journal-title":"Int J Cancer"},{"issue":"1","key":"1585_CR11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12964-023-01065-9","volume":"21","author":"D Sun","year":"2023","unstructured":"Sun D, et al. Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency. Cell Commun Signal. 2023;21(1):48.","journal-title":"Cell Commun Signal"},{"issue":"4","key":"1585_CR12","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4143\/crt.2022.1450","volume":"55","author":"SH Lee","year":"2023","unstructured":"Lee SH, et al. ARID1A mutation from targeted next-generation sequencing predicts primary resistance to gemcitabine and cisplatin chemotherapy in advanced biliary tract cancer. Cancer Res Treat. 2023;55(4):1291\u2013302.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"1585_CR13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s10147-015-0811-x","volume":"20","author":"H Itamochi","year":"2015","unstructured":"Itamochi H, et al. Loss of ARID1A expression is associated with poor prognosis in patients with stage I\/II clear cell carcinoma of the ovary. Int J Clin Oncol. 2015;20(5):967\u201373.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"1585_CR14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10555-023-10102-5","volume":"42","author":"D Reddy","year":"2023","unstructured":"Reddy D, Bhattacharya S, Workman JL. (mis)-Targeting of SWI\/SNF complex(es) in cancer. Cancer Metastasis Rev. 2023;42(2):455\u201370.","journal-title":"Cancer Metastasis Rev"},{"issue":"6480","key":"1585_CR15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.aaz9761","volume":"367","author":"S He","year":"2020","unstructured":"He S, et al. Structure of nucleosome-bound human BAF complex. Science. 2020;367(6480):875\u201381.","journal-title":"Science"},{"issue":"12","key":"1585_CR16","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1158\/1535-7163.MCT-21-0433","volume":"20","author":"K Mardinian","year":"2021","unstructured":"Mardinian K, et al. SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy. Mol Cancer Ther. 2021;20(12):2341\u201351.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1585_CR17","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1038\/s41467-022-31197-4","volume":"13","author":"C Yu","year":"2022","unstructured":"Yu C, et al. ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription. Nat Commun. 2022;13(1):3501.","journal-title":"Nat Commun"},{"issue":"7730","key":"1585_CR18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-018-0658-1","volume":"563","author":"L Chang","year":"2018","unstructured":"Chang L, et al. The SWI\/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature. 2018;563(7730):265\u20139.","journal-title":"Nature"},{"issue":"5","key":"1585_CR19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","volume":"24","author":"J Shen","year":"2018","unstructured":"Shen J, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556\u201362.","journal-title":"Nat Med"},{"issue":"3","key":"1585_CR20","doi-asserted-by":"crossref","first-page":"e111998","DOI":"10.15252\/embj.2022111998","volume":"42","author":"V Mengoli","year":"2023","unstructured":"Mengoli V, et al. WRN helicase and mismatch repair complexes independently and synergistically disrupt cruciform DNA structures. EMBO J. 2023;42(3):e111998.","journal-title":"EMBO J"},{"issue":"21","key":"1585_CR21","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1158\/0008-5472.CAN-11-1562","volume":"71","author":"B Guan","year":"2011","unstructured":"Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI\/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718\u201327.","journal-title":"Cancer Res"},{"key":"1585_CR22","doi-asserted-by":"crossref","unstructured":"Sun X, et al. Arid1a has context-dependent oncogenic and tumor suppressor functions in liver cancer. Cancer Cell. 2017;32(5): p. 574\u2013589.e6.","DOI":"10.1016\/j.ccell.2017.10.007"},{"issue":"1","key":"1585_CR23","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/s41467-020-16416-0","volume":"11","author":"Y Suryo Rahmanto","year":"2020","unstructured":"Suryo Rahmanto Y, et al. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nat Commun. 2020;11(1):2717.","journal-title":"Nat Commun"},{"issue":"4","key":"1585_CR24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3802\/jgo.2013.24.4.376","volume":"24","author":"TL Mao","year":"2013","unstructured":"Mao TL, Shih IM. The roles of ARID1A in gynecologic cancer. J Gynecol Oncol. 2013;24(4):376\u201381.","journal-title":"J Gynecol Oncol"},{"key":"1585_CR25","doi-asserted-by":"crossref","unstructured":"Wang Y, et al. Chromatin remodelling molecule ARID1A determines metastatic heterogeneity in triple-negative breast cancer by competitively binding to YAP. Cancers (Basel), 2023;15(9).","DOI":"10.3390\/cancers15092447"},{"issue":"11","key":"1585_CR26","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/1878-0261.13193","volume":"16","author":"C Megino-Luque","year":"2022","unstructured":"Megino-Luque C, et al. ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma. Mol Oncol. 2022;16(11):2235\u201359.","journal-title":"Mol Oncol"},{"key":"1585_CR27","doi-asserted-by":"crossref","unstructured":"Takahashi K, et al. Treatment strategies for ARID1A-deficient ovarian clear cell carcinoma. Cancers (Basel). 2021;13(8).","DOI":"10.3390\/cancers13081769"},{"issue":"2","key":"1585_CR28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/modpathol.2011.161","volume":"25","author":"A Katagiri","year":"2012","unstructured":"Katagiri A, et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol. 2012;25(2):282\u20138.","journal-title":"Mod Pathol"},{"key":"1585_CR29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2018.04.013","volume":"427","author":"Q Luo","year":"2018","unstructured":"Luo Q, et al. ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2. Cancer Lett. 2018;427:9\u201317.","journal-title":"Cancer Lett"},{"issue":"2","key":"1585_CR30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s43018-020-00160-x","volume":"2","author":"S Wu","year":"2021","unstructured":"Wu S, et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nat Cancer. 2021;2(2):189\u2013200.","journal-title":"Nat Cancer"},{"key":"1585_CR31","unstructured":"World Health Organization. Endometriosis. 2023. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/endometriosis. Cited 2023 July."},{"issue":"3","key":"1585_CR32","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ygyno.2021.06.033","volume":"162","author":"A Gadducci","year":"2021","unstructured":"Gadducci A, et al. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2021;162(3):741\u201350.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1585_CR33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41588-022-01254-1","volume":"55","author":"MAS Fonseca","year":"2023","unstructured":"Fonseca MAS, et al. Single-cell transcriptomic analysis of endometriosis. Nat Genet. 2023;55(2):255\u201367.","journal-title":"Nat Genet"},{"issue":"19","key":"1585_CR34","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1614814","volume":"376","author":"MS Anglesio","year":"2017","unstructured":"Anglesio MS, et al. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med. 2017;376(19):1835\u201348.","journal-title":"N Engl J Med"},{"key":"1585_CR35","unstructured":"Faizan U, Muppidi V. Uterine cancer. Treasure Island, FL: StatPearls 2023."},{"issue":"1","key":"1585_CR36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/path.5566","volume":"253","author":"L Li","year":"2021","unstructured":"Li L, et al. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. J Pathol. 2021;253(1):119\u201328.","journal-title":"J Pathol"},{"issue":"2","key":"1585_CR37","doi-asserted-by":"crossref","first-page":"100045","DOI":"10.1016\/j.modpat.2022.100045","volume":"36","author":"S Asaka","year":"2023","unstructured":"Asaka S, et al. ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis. Mod Pathol. 2023;36(2):100045.","journal-title":"Mod Pathol"},{"issue":"2","key":"1585_CR38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ygyno.2020.10.043","volume":"160","author":"S Matsuzaki","year":"2021","unstructured":"Matsuzaki S, et al. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021;160(2):586\u2013601.","journal-title":"Gynecol Oncol"},{"key":"1585_CR39","doi-asserted-by":"crossref","unstructured":"Leskela S, et al. Molecular basis of tumor heterogeneity in endometrial carcinosarcoma. Cancers (Basel). 2019;11(7).","DOI":"10.3390\/cancers11070964"},{"issue":"12","key":"1585_CR40","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0038-1673678","volume":"40","author":"J Moreira-Barros","year":"2018","unstructured":"Moreira-Barros J, Huang KG, Tsai TH. Radiation-Induced Uterine Carcinosarcoma after Concurrent Chemoradiotherapy for Cervical Squamous Cell Carcinoma. Rev Bras Ginecol Obstet. 2018;40(12):800\u20132.","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"1","key":"1585_CR41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tjog.2012.01.018","volume":"51","author":"K Kahraman","year":"2012","unstructured":"Kahraman K, et al. Uterine carcinosarcoma associated with pelvic radiotherapy for sacral chordoma: a case report. Taiwan J Obstet Gynecol. 2012;51(1):89\u201392.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"1585_CR42","doi-asserted-by":"crossref","first-page":"106977","DOI":"10.1016\/j.ijscr.2022.106977","volume":"94","author":"TB Ahmed","year":"2022","unstructured":"Ahmed TB, et al. Radiotherapy-induced uterine cacinosarcoma: A case report and review of the literature. Int J Surg Case Rep. 2022;94:106977.","journal-title":"Int J Surg Case Rep"},{"issue":"2","key":"1585_CR43","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.3802\/jgo.2018.29.e22","volume":"29","author":"K Matsuo","year":"2018","unstructured":"Matsuo K, et al. Trends of uterine carcinosarcoma in the United States. J Gynecol Oncol. 2018;29(2):e22.","journal-title":"J Gynecol Oncol"},{"issue":"12","key":"1585_CR44","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.52586\/5035","volume":"26","author":"F Gao","year":"2021","unstructured":"Gao F, et al. ARID1A-mutated cervical cancer depends on the activation of YAP signaling. Front Biosci (Landmark Ed). 2021;26(12):1411\u201321.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"1585_CR45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2023.05.071","volume":"175","author":"J Li","year":"2023","unstructured":"Li J, et al. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer. Gynecol Oncol. 2023;175:133\u201341.","journal-title":"Gynecol Oncol"},{"key":"1585_CR46","doi-asserted-by":"crossref","first-page":"792003","DOI":"10.3389\/fonc.2021.792003","volume":"11","author":"H Wen","year":"2021","unstructured":"Wen H, et al. Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature. Front Oncol. 2021;11:792003.","journal-title":"Front Oncol"},{"key":"1585_CR47","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.2147\/CMAR.S201415","volume":"11","author":"J Zhao","year":"2019","unstructured":"Zhao J, et al. HPV infection associated DNA damage correlated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan. China Cancer Manag Res. 2019;11:7197\u2013210.","journal-title":"China Cancer Manag Res"},{"key":"1585_CR48","doi-asserted-by":"crossref","unstructured":"Ruiz FJ, et al. Genomic characterization and therapeutic targeting of HPV undetected cervical carcinomas. Cancers (Basel). 2021;13(18).","DOI":"10.3390\/cancers13184551"},{"issue":"6","key":"1585_CR49","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/s41418-019-0475-6","volume":"27","author":"Q Luo","year":"2020","unstructured":"Luo Q, et al. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb\/E2F1\/c-Myc-mediated cancer stemness. Cell Death Differ. 2020;27(6):1981\u201397.","journal-title":"Cell Death Differ"},{"key":"1585_CR50","doi-asserted-by":"crossref","first-page":"686879","DOI":"10.3389\/fimmu.2021.686879","volume":"12","author":"EK Egger","year":"2021","unstructured":"Egger EK, et al. Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report. Front Immunol. 2021;12:686879.","journal-title":"Front Immunol"},{"issue":"7","key":"1585_CR51","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.ajpath.2021.03.013","volume":"191","author":"X Wang","year":"2021","unstructured":"Wang X, et al. Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre. Am J Pathol. 2021;191(7):1281\u201391.","journal-title":"Am J Pathol"},{"issue":"9","key":"1585_CR52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/apm.12977","volume":"127","author":"A Raffone","year":"2019","unstructured":"Raffone A, et al. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS. 2019;127(9):597\u2013606.","journal-title":"APMIS"},{"issue":"1","key":"1585_CR53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3802\/jgo.2014.25.1.58","volume":"25","author":"Y Yokoyama","year":"2014","unstructured":"Yokoyama Y, et al. Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. J Gynecol Oncol. 2014;25(1):58\u201363.","journal-title":"J Gynecol Oncol"},{"issue":"18","key":"1585_CR54","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1158\/1078-0432.CCR-18-4222","volume":"25","author":"Y Park","year":"2019","unstructured":"Park Y, et al. Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP Inhibitor therapy. Clin Cancer Res. 2019;25(18):5584\u201394.","journal-title":"Clin Cancer Res"},{"key":"1585_CR55","doi-asserted-by":"crossref","first-page":"999626","DOI":"10.3389\/fonc.2022.999626","volume":"12","author":"S Xu","year":"2022","unstructured":"Xu S, et al. Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy. Front Oncol. 2022;12:999626.","journal-title":"Front Oncol"},{"key":"1585_CR56","doi-asserted-by":"crossref","unstructured":"Li JL, Soble Z, Baro W, Lee M, Damast H, Contessa S, Huang JG. ARID1A deficiency as a biomarker for sensitivity to radiation and ATR inhibition. In: Abstracts of the 2022 Society of Gynecologic Oncology Annual Meeting. 2022.","DOI":"10.1016\/S0090-8258(22)01456-1"},{"key":"1585_CR57","doi-asserted-by":"crossref","unstructured":"Andrade D, et al. HuR reduces radiation-induced DNA damage by enhancing expression of ARID1A. Cancers (Basel). 2019;11(12).","DOI":"10.3390\/cancers11122014"},{"issue":"2","key":"1585_CR58","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/modpathol.2013.144","volume":"27","author":"G Allo","year":"2014","unstructured":"Allo G, et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol. 2014;27(2):255\u201361.","journal-title":"Mod Pathol"},{"issue":"11","key":"1585_CR59","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel S, et al. CDK4\/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018;28(11):911\u201325.","journal-title":"Trends Cell Biol"},{"issue":"2","key":"1585_CR60","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, et al. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4\/6 Kinase Inhibitors. Cancer Discov. 2022;12(2):356\u201371.","journal-title":"Cancer Discov"},{"key":"1585_CR61","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","volume":"4","author":"C Porta","year":"2014","unstructured":"Porta C, Paglino C, Mosca A. Targeting PI3K\/Akt\/mTOR Signaling in Cancer. Front Oncol. 2014;4:64.","journal-title":"Front Oncol"},{"issue":"21","key":"1585_CR62","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-15-2996","volume":"22","author":"K Berns","year":"2016","unstructured":"Berns K, et al. Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. Clin Cancer Res. 2016;22(21):5238\u201348.","journal-title":"Clin Cancer Res"},{"key":"1585_CR63","doi-asserted-by":"crossref","unstructured":"Silva-Oliveira R, et al. Clinical significance of ARID1A and ANXA1 in HER-2 positive breast cancer. J Clin Med, 2020;9(12).","DOI":"10.3390\/jcm9123911"},{"issue":"1","key":"1585_CR64","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1631\/jzus.B2200272","volume":"24","author":"J Mo","year":"2023","unstructured":"Mo J, et al. A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer. J Zhejiang Univ Sci B. 2023;24(1):64\u201377.","journal-title":"J Zhejiang Univ Sci B"},{"key":"1585_CR65","doi-asserted-by":"crossref","unstructured":"Shishova A, et al. Enteroviruses manipulate the unfolded protein response through multifaceted deregulation of the Ire1-Xbp1 pathway. Viruses. 2022;14(11).","DOI":"10.3390\/v14112486"},{"issue":"20","key":"1585_CR66","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/0008-5472.CAN-21-1545","volume":"81","author":"JA Zundell","year":"2021","unstructured":"Zundell JA, et al. Targeting the IRE1alpha\/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers. Cancer Res. 2021;81(20):5325\u201335.","journal-title":"Cancer Res"},{"key":"1585_CR67","doi-asserted-by":"crossref","unstructured":"Cheng M, et al. The mitochondrial PHB2\/OMA1\/DELE1 pathway cooperates with endoplasmic reticulum stress to facilitate the response to chemotherapeutics in ovarian cancer. Int J Mol Sci. 2022;23(3).","DOI":"10.3390\/ijms23031320"},{"issue":"1","key":"1585_CR68","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1038\/s41467-021-25684-3","volume":"12","author":"J Lin","year":"2021","unstructured":"Lin J, et al. Targeting the IRE1alpha\/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nat Commun. 2021;12(1):5321.","journal-title":"Nat Commun"},{"key":"1585_CR69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fonc.2018.00097","volume":"8","author":"M Velayutham","year":"2018","unstructured":"Velayutham M, et al. Discovering a Reliable Heat-Shock Factor-1 Inhibitor to Treat Human Cancers: Potential Opportunity for Phytochemists. Front Oncol. 2018;8:97.","journal-title":"Front Oncol"},{"issue":"45","key":"1585_CR70","doi-asserted-by":"crossref","first-page":"18378","DOI":"10.1073\/pnas.1115031108","volume":"108","author":"S Santagata","year":"2011","unstructured":"Santagata S, et al. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A. 2011;108(45):18378\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1585_CR71","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1021\/acs.jmedchem.3c00156","volume":"66","author":"AE Pasqua","year":"2023","unstructured":"Pasqua AE, et al. HSF1 Pathway Inhibitor Clinical Candidate (CCT361814\/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies. J Med Chem. 2023;66(8):5907\u201336.","journal-title":"J Med Chem"},{"key":"1585_CR72","doi-asserted-by":"crossref","unstructured":"Stewart JR, Poradosu E, Woods A, Shemesh S, Clarke P, Te Poele R, Workman P, Banerjee S. 8P NXP800 versus cisplatin in ARID1a-mutated ovarian clear cell carcinoma xenograft models. ESMO Open. 2023;8(1, Suppl 1):100862.","DOI":"10.1016\/j.esmoop.2023.100862"},{"issue":"11","key":"1585_CR73","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/ijgc-2021-002973","volume":"31","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI). Int J Gynecol Cancer. 2021;31(11):1471\u20135.","journal-title":"Int J Gynecol Cancer"},{"key":"1585_CR74","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson CT, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837.","journal-title":"Nat Commun"},{"issue":"33","key":"1585_CR75","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1038\/s41388-018-0300-6","volume":"37","author":"K Berns","year":"2018","unstructured":"Berns K, et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene. 2018;37(33):4611\u201325.","journal-title":"Oncogene"},{"key":"1585_CR76","doi-asserted-by":"crossref","first-page":"e2300235","DOI":"10.1200\/PO.23.00235","volume":"7","author":"LR Duska","year":"2023","unstructured":"Duska LR, et al. Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib\/IIa Study of PLX2853\/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. JCO Precis Oncol. 2023;7:e2300235.","journal-title":"JCO Precis Oncol"},{"key":"1585_CR77","doi-asserted-by":"crossref","unstructured":"Ogiwara H, et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell. 2019;35(2): 177\u2013190.e8.","DOI":"10.1016\/j.ccell.2018.12.009"},{"key":"1585_CR78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10.","journal-title":"Biomark Res"},{"issue":"3","key":"1585_CR79","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","volume":"21","author":"BG Bitler","year":"2015","unstructured":"Bitler BG, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21(3):231\u20138.","journal-title":"Nat Med"},{"issue":"7","key":"1585_CR80","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.apsb.2023.03.013","volume":"13","author":"D Zheng","year":"2023","unstructured":"Zheng D, et al. Emerging roles of Aurora-A kinase in cancer therapy resistance. Acta Pharm Sin B. 2023;13(7):2826\u201343.","journal-title":"Acta Pharm Sin B"},{"issue":"24","key":"1585_CR81","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-18-1244","volume":"24","author":"S Lheureux","year":"2018","unstructured":"Lheureux S, et al. A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. Clin Cancer Res. 2018;24(24):6168\u201374.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1585_CR82","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1172\/JCI134402","volume":"130","author":"J Li","year":"2020","unstructured":"Li J, et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest. 2020;130(5):2712\u201326.","journal-title":"J Clin Invest"},{"issue":"10","key":"1585_CR83","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1585_CR84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13048-020-00751-3","volume":"13","author":"YC Lin","year":"2020","unstructured":"Lin YC, et al. Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. J Ovarian Res. 2020;13(1):143.","journal-title":"J Ovarian Res"},{"key":"1585_CR85","doi-asserted-by":"crossref","first-page":"1079253","DOI":"10.3389\/fimmu.2022.1079253","volume":"13","author":"CH Kao","year":"2022","unstructured":"Kao CH, et al. Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma. Front Immunol. 2022;13:1079253.","journal-title":"Front Immunol"},{"key":"1585_CR86","doi-asserted-by":"crossref","first-page":"955466","DOI":"10.3389\/fgene.2023.955466","volume":"14","author":"M Zhao","year":"2023","unstructured":"Zhao M, Li W. Metabolism-associated molecular classification of uterine corpus endometrial carcinoma. Front Genet. 2023;14:955466.","journal-title":"Front Genet"},{"key":"1585_CR87","doi-asserted-by":"crossref","first-page":"1043870","DOI":"10.3389\/fgene.2022.1043870","volume":"13","author":"C Ji","year":"2022","unstructured":"Ji C, He Y, Wang Y. Identification of necroptosis subtypes and development of necroptosis-related risk score model for in ovarian cancer. Front Genet. 2022;13:1043870.","journal-title":"Front Genet"},{"key":"1585_CR88","doi-asserted-by":"crossref","first-page":"1067666","DOI":"10.3389\/fgene.2023.1067666","volume":"14","author":"W Lai","year":"2023","unstructured":"Lai W, et al. Characterization of the microenvironment in different immune-metabolism subtypes of cervical cancer with prognostic significance. Front Genet. 2023;14:1067666.","journal-title":"Front Genet"},{"issue":"1","key":"1585_CR89","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/GRF.0000000000000742","volume":"66","author":"N Adebayo","year":"2023","unstructured":"Adebayo N, et al. Tackling gynecologic cancer disparities: an assessment of 2 interventions for improving information exchange with racial\/ethnic communities. Clin Obstet Gynecol. 2023;66(1):43\u201352.","journal-title":"Clin Obstet Gynecol"},{"issue":"1","key":"1585_CR90","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2021.07.017","volume":"163","author":"RC Arend","year":"2021","unstructured":"Arend RC, et al. Systematic next generation sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: results from a prospective cohort study. Gynecol Oncol. 2021;163(1):85\u201392.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1585_CR91","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ygyno.2022.04.014","volume":"166","author":"AM Wilhite","year":"2022","unstructured":"Wilhite AM, et al. Molecular profiles of endometrial cancer tumors among Black patients. Gynecol Oncol. 2022;166(1):108\u201316.","journal-title":"Gynecol Oncol"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-024-01585-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-024-01585-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-024-01585-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T10:11:50Z","timestamp":1722334310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-024-01585-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1585"],"URL":"https:\/\/doi.org\/10.1007\/s43032-024-01585-w","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable for this Article Type (Review).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not Applicable for this Article Type (Review).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not Applicable for this Article Type (Review).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"G.S.H. is the Inventor on U.S. Patent 17102992 for Targeting of ARID1A-Deficient Cancers. G.S.H. has received consulting fees from Glaxo Smith Kline and AstraZeneca, outside of the scope of this work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The other authors (J. M., N. J., Z.S.) have no relevant financial or non-financial interests to disclose.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}